We developed monoclonal antibodies against Drosophila topoisomerase 11 and studied the intracellular forms and the in vivo and in vitro proteolytic degradation of the enzyme. In purified enzyme preparations polyclonal sera and monoclonal antibodies recognized several polypeptides in the 170-132 kD molecular weight range. In vivo, however, the pattern was much simpler. In Drosophila embryos, pupae, fly heads and Schneider S3 tissue culture cells topoisomerase II appeared as a single 166 kD polypeptide. In Drosophila embryos, with two monoclonal antibodies topoisomerase II appeared as a doublet composed of the 166 kD canonical form and a slightly higher molecular weight polypeptide. Topoisomerase II was shown to be present also in fly heads which are composed entirely of nonproliferative tissues.
INTRODUCTION
In eukaryotes type II topoisomerases have proven to be essential in chromosome disjunction at mitosis (1, 2, 3, 4, 5, 6, 7) . In addition its involvement has been assumed in sister chromatid exchange (8, 9) , in the regulation of transcription (10, 11) and in the organisation of chromosomal loop domains (12, 13) . Topoisomerase II was found to be a structural component of the mitotic chromosome scaffold (14) and of the nuclear matrix of interphase nuclei (15). The enzyme is a homodimer of a polypeptide with a molecular weight between 166-180 kD, species depending (16, 17, 18, 19) . Topoisomerase II was shown to be a specific marker for cell proliferation, missing in nonproliferative tissues (26) .
The structure of Drosophila topoisomerase II was studied in detail. In purified enzyme preparations immunological and enzymatic assays revealed at least three high molecular weight forms. The most abundant 166 kD form is thought to be the full length polypeptide, while the 155 and 132 kD forms are presumed to be degradation products (17, 18) . In total embryonic protein extracts prepared by rapid lysis of Drosophila embryos a similar immunoreactive polypeptide pattern was detected with polyclonal anti-topoisomerase II antibodies. This observation suggested that topoisomerase II exists in multiple forms in vivo and seemed to exclude the possibility that the lower molecular weight forms in the purified enzyme preparations were generated by proteolysis during the purification (20) . It was also suggested that in vivo proteolysis generates the multiplicity of topoisomerase II, and this might be essential in the regulation of this multifunctional enzyme (20) .
In this study using monoclonal antibodies against Drosophila topoisomerase II we demonstrate that the in vivo multiplicity reported in the literature is due to aspecific in vitro proteolysis, the in vivo form of the enzyme is a 166 kD polypeptide which is present both in proliferative and in nonproliferative Drosophila tissues.
MATERIALS AND METHODS
Assay methods for topoisomerase II. The relaxation activity of the purified enzyme was tested by incubating 0.3 ug supercoiled plasmid DNA in 25 ul relaxation assay buffer (10 mM tris. Cl pH 7.5, 50 mM KC1, 100 mM NaCl, 0.1 mM EDTA, 10 mM MgCl,, 1 mM ATP, 1 mM DTT) at 30°C for 20 min. with appropriate dilutions of topoisomerase II. The distribution of the topoisomers was analysed by agarose gel electrophoresis as described previously (11). The catenation activity of purified topoisomerase II was assayed according to Shelton et. al. (18) . Purification of toooisomerase II. From 6-18 hours Drosophila embryos topoisomerase II was purified according to Shelton et. al. (18) . Alternative procedure was devised to purify the enzyme either from 12-16 hours old embryos or from pupae. Embryos stored frozen at -70 C were thawed on ice, dechorionated in half strength Chlorax for 2 min. and washed thoroughly with 0.7 % NaCl, 0.01 % Triton X-100. To collect pupae eggs were layed for 2 hours on feeding plates. To achive synchronous growth the density of the embryos were kept low. Pupae were washed off after seven days incubation at 25°C, when the red color of the eye appeared. After thorough washing with distilled water the pupae were blotted damp, frozen on dry ice and stored at -70°c. 200 g of embryo or pupae were thawed, resuspended into 800 ml of 1 M NaCl, 30 mM tris. Cl pH 7.9, 10 mM EDTA, 1 mM EGTA, 0.1 mM PMSF and ho.-nogenised in Waring blendor for 2 min. with full speed. The crude extract was filtered through 150 urn nitex screen and centrifuged for 30 min. at 14003 rpm. 0.1 volurn of 5 M fJaCl and 0.1 volume of 5 % polyethylenimine (Sigma) diluted in 20 mM tris. Cl and neutralized to pH 7.9 was added to the supernatant under continous stirring. After an additional 10 min. stirring the precipitate was removed by centrifugation (10 min. at 14000 rpm). This crude extract was fractionated with ammonium sulfate and chromatographed on hydroxylapatite (Boehringer, 4x15 cm column) exactly as described by Shelton et. al. (18) .
The active fractions were dialysed against buffer A (15 mM K phosphate pH 7.2, 100 mM NaCl, 1 mM EDTA, 0.1 mM DTT, 10 % glycerol) and loaded onto a 2.5x15 cm Q-Sepharose FF (Pharmacia) column equilibrated with buffer A. With linear salt gradient (300 ml, 0.1-1 M NaCl in buffer A) the enzyme eluted between 0.3-0.4 M NaCl, while topoisomerase I was quantitatively recovered in the flow-through.
The active fractions were pooled, diluted in small aliquots with NaCl free buffer A to 0.2 M final NaCl concentration (controlled with a conductivity meter) and loaded immediately onto 2x12 cm phosphocellulose column (Whathman Pll), which was equilibrated with buffer A. With linear salt gradent (240 ml, 0.2-0.7 M NaCl in buffer A) the enzyme eluted between 0.4-0.5 M NaCl.
The active fractions were pooled, diluted in small aliquots to 0.2 M final NaCl concentration with NaCl free buffer A and loaded immediately onto a 1x15 cm heparin-agarose column (Sigma) which was equlibrated with buffer A. With linear salt gradient (80 ml, 0.2-1.2 M NaCl in buffer A) the enzyme eluted between 0.8-1 M NaCl.
The active fractions were pooled and concentrated on a small phosphocellulose column. The enzyme was eluted with buffer A containing 0.7 M NaCl and only 5 % glycerol. This was layered on 15-40 % glycerol gradient in buffer A containing 0.7 M NaCl and centrifuged at 47000 rpm for 48 hours at 4°C in a Beckman SW 50.1 rotor. The active fractions were supplemented with glycerol to 50 % concentration and stored at -20°C.
The enzyme was purified to apparent homogeneity with this procedure (Fig. 1) , with a yield of about 0.6-0.8 mg/200 g of pupae or 1.4-1.8 mg/200 g of embryo. Preparation of total embryonal protein extract. 4-12 hours old fresh embryos were dechorionated in half stength Chlorax for 2 min., washed thoroughly with distilled water and dissolved immediately in SDS protein electrophoresis sample buffer (60 mM tris. Cl pH 6.8, 2.5 % sodium dodecyl sulfate, 5 % beta-mercaptoethanol and 10 % glycerol) with a Dounce homogenizer. The extract was boiled for 2 min., and centrifuged at 12000 rpm for 10 min. Protein extract from tissue culture cells was prepared as described for embryos. Fly heads were obtained from starving flies according to Bossy et. al. (30) with the only modification that mechanical shaking was replaced with sonication for 2 min. in liquid nitrogen using a Branson B30 sonifier (output setting of 4). Total protein extract was prepared by grinding fly heads or pupae in a mortar with the protein sample buffer before boiling. The extracts were clarified by centrifugation and stored at -20°C. Electrophoretic separation of proteins was done on 5-20 % gradient SDS-polyacrilamide gels according to Laemmli (28). Immunoperoxidase staining. Electrophoretic transfer of proteins was made according to Towbin et. al. (29) using a modified buffer system (10 mM imidazole, 30 mM glycyl-glycine, 20 % methanol, 0.1 % SDS). Aspecific binding sites of the nitrocellulose filters were blocked in phosphate buffered saline containing 20 % fetal calf serum, 1 % bovine serum albumine and 0.05 % Tween 20. Undiluted hybridoma supernatants and ascites fluids diluted 1:50 served as primary antibodies. Antibody binding was detected with HRPO conjugated anti-mouse immunoglobulin (Dako) diluted 1:250, and visualised by HRP Color Development Reagent (BioRad).
RESULTS
To study the intracellular forms of Drosophila topoisomerase II we first developed polyclonal anti-sera by immunising mice with 10 ug of Drosophila topoisomerase II purified from 6-18 hours old embryos according to the procedure of Shelton et. al. (18) . The polyclonal sera were tested in a protein blotting assay on homogeneous topoisomerase II. Spleen cells of the immunised mice were fused with Sp 2/0 cells and hybridoma clones were established according to standard protocols (21). These clones were assayed by the ELISA test using homogeneous topoisomerase II, and 48 positive clones were selected. In a protein blotting assay with homogeneous topoisomerase II prepared either from Drosophila embryos or from pupae five clones were chosen and after recloning were used in the subsequent studies. All of these monoclonals reacted with the 170-132 kD set of polypeptides characteristic of purified topoisomerase II (20). However, the reactivities of the monoclonal antibodies toward the individual high molecular weight polypeptides were different and resulted in a characteristic immunoreactive pattern ( Fig.l lanes 1-3) . This suggests that our monoclonal antibodies recognize different epitopes on the enzyme, and these epitopes are unevenly distributed on the different polypeptides. We also tested these clones on mouse and alfalfa protein extracts and found that they recognized different antigens characteristic of the individual monoclonals (in preparation).
This further supports the above suggestion of different epitope specificity.
To study the intracellular form of topoisomerase II a total protein extract was prepared by rapid lysis of fresh Drosophila embryos in SDS protein electrophoresis sample buffer as described in Methods. All the monoclonal antibodies recognized a single 166 kD polypeptide in this total protein extract. As shown in Fig.2A there was no sign of multiplicity in the 170-132 kD molecular weight range characteristic of purified enzyme preparations. After a prolonged electrophoresis of total embryonic protein extract a slightly higher molecula.r weight immunoreactive band also appeared using T21C2 and T22C5 antibodies on the subsequent immunoblots Beside the 166 kD band, T21D4 monclonal antibody and the polyclonal sera also recognized a 38 kD polypeptide ( Fig. 2A lanes 1, 2,7 and 12, and Fig.  2B lanes 1,4) . This is probably a more stable in vivo degradation product of the enzyme because its intensity on immunoblots of total protein extracts prepared from different Drosophila tissues is comparable with the intensity of the 166 kD form (see later). Furthermore, antigen-affinity purified T21D4 antibody from the 38 kD antigen recognized the 166 kD form of the enzyme in reblotting experiments, and vice versa, indicating that the 166 kD and 38 kD polypeptides are related (data not shown).
The intracellular pattern of Drosophila topoisomerase II changed dramatically when the embryos were first frozen on dry ice, stored at -80°C (from 1 week up to three months were tested), then thawed on ice, and dechorionated and lysed in the same way described for fresh embryos. As shown in Fig. 2C the intensity of the 166 kO polypeptide is greatly reduced, a strong 160 kD and several weak immunoreactive bands appeared in the 160-110 kD molecular weight range. The major proteolytic fragment was recognized by all three monclonal antibodies tested. This observation strongly suggests that the multiplicity in purified enzyme preparations is due to in vitro proteolysis. This assumption is further supported by the observation that topoisomerase II in total protein extract of fresh embryos showed extensive degradation when stored for a week in SDS protein sample buffer at -20°C. The 166 kD band was split into a doublet, and new degradation products appeared in the 80 kD and 28 kD range (data not shown).
We have also studied the in vivo form of topoisomerase II in Drosophila pupae, fly heads and Schneider S3 tissue culture cells. The 166 kD polypeptide was the predominant intracellular form of topoisomerase II regardless of the source (Fig. 3) .
By comparing the protein content of total protein extracts prepared from fly heads, pupae, Schneider S3 tissue culture cells and embryos (Fig. 3A) to the topoisomerase II level detected by immunostaining (Fig. 3B) , we can estimate the relative abundance of topoisomerase II in these samples. In agreement with Heck and Earnshaw (26) and Fairman and Brutlag (27) a correlation was found between the cellular content of topoisomerase II and the proliferative activity of the tissues studied. Drosophila embryos, with the highest proliferative activity have the highest relative topoisomerase II content. In contradiction to Heck and Earnshaw, who could not detect the presence of topoisomerase II in nonproliferative lymphoid cells or in nonproliferative myotubes using polyclonal antibody (26), however, we unambiguously demonstrated the presence of this enzyme in the fly head which is composed entirely of nonproliferative tissues.
Assuming that the 38 kD polypeptide, which is recognized by the T21D4 monclonal is a stable in vivo degradation product, it follows that the low cellular topoisomerase II content of the nonproliferative fly head tissues is due to a lower synthesis rate and not to an enhanced in vivo degradation of the enzyme, because the relative proportion of the 38 kD polypeptide is not higher in fly heads than in embryos.
DISCUSSION
ONA topoisomerase II is a multifunctional enzyme which is implicated in many vital cellular reactions involving DNA. In the regulation of these cellular reactions protein factors acting in concert with topoisomerase II may play a role. Alternatively, multiple cellular forms of topoisomerase II, generated with postsynthetic modification of the enzyme may also be responsible for this diversity. This latter assumption is supported by the observation that topoisomerase II purified to apparent homogeneity from Drosophila melanogaster always contained several high molecular weight polypeptides, these polypeptides were structurally and immunologically related and all of these polypeptides were active in the topoisomerization reaction (17). Furthermore, similar multiple topoisomerase II profile was observed by immunological test in protein extracts prepared by rapid lysis of total embryos in SDS protein sample buffer, suggesting that the multiplicity in the purified enzyme is not due to in vitro proteolysis (20) .
It was also suggested that in vivo proteolysis generates the multiplicity of topoisomerase II, and this might be essential in the regulation of this multifunctional enzyme (20).
We have generated monoclonal antibodies against Drosophila topoisomerase II and studied the in vitro structural diversity in purified enzyme preparations and also the in vivo heterogeneity in different Drosophila tissues. We have confirmed the heterogeneity in the purified enzyme Monoclonal antibodies revealed, however, a real in vivo heterogeneity of topoisomerase II. After prolonged electrophoresis of total protein extract of fresh embryos a second immunoreactive band appeared with two monoclonal
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antibodies. As two other monoclonal antibodies detected only a single immunoreactive band from the same extract under the same electrophoretic conditions, this heterogeneity reflects the existence of two distinct forms of topoisomerase II. This second form of the enzyme has a slightly higher molecular weight than the canonical 166 kD form, indicating that it is not a degradation product. In Drosophila melanogaster topoisomerase II is coded by a single copy gene (22) . The observed in vivo heterogeneity (Fig. 28 lanes 3 and 5) thus may only arise from differential splicing of the mRNA or a postsynthetic modification of a fraction of the cellular topoisomerase II. In vitro phosphorylation of topoisomerase II by caseine kinase II resulted in a 3-fold stimulation of the relaxation activity (23), while poly(AOP-ribosylation) inhibited both the relaxation, the catenation and the unknotting activity (24). These observations may support the significance of postsynthetic modifications in generating the enzyme multiplicity. Murine P388 leukaemia cells contain two immunologically and structurally different topoisomerase II forms (25), suggesting that the in vivo multiplicity of the enzyme may be more general.
Our studies with monoclonal anti-topoisomerase II antibodies unambiguously demonstrated the presence of this enzyme in nonproliferative Drosophila tissues. This is in contradiction with the results of Heck and Earnshaw (26) who claim that topoisomerase II is a specific marker for cell proliferation, the enzyme is undetectable in nonproliferative tissues and thus is not required for transciption, but only for the replication of DNA. This discrepancy may be due to differences of species studied or may be due to a higher sensitivity of the monocloi;ai antibodies. Our observation supports the involvement of topoisomerase II in vital cellular processes in nonproliferative tissues, and the assumption that topoisomerase II is required only for the replication of the DNA is at least not general.
In this study the application of monoclonal anti-topoisomerase II antibodies revealed that the in vivo form of Drosophila topoisomerase II is the 166 kD polypeptide. The slightly higher molecular weight form recognized by two monoclonal antibodies might merely be a product of postsynthetic modification(s) involved in the regulation of enzyme activity. It is apparent from the results that topoisomerase II is a detectable component of nonproliferative tissues too.
